Financial Lp Hrt Buys 7,851 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 7,851 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were bought at an average cost of $3.54 per share, for a total transaction of $27,792.54. Following the completion of the transaction, the insider directly owned 90,407 shares in the company, valued at $320,040.78. This trade represents a 9.51% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total transaction of $31,667.22.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Price Performance

SHPH stock traded down $0.24 during midday trading on Tuesday, hitting $3.26. 109,982 shares of the stock traded hands, compared to its average volume of 543,961. Shuttle Pharmaceuticals Holdings, Inc. has a 1-year low of $2.90 and a 1-year high of $55.90. The stock’s fifty day simple moving average is $5.57 and its 200-day simple moving average is $10.46. The firm has a market cap of $2.08 million, a P/E ratio of -0.07 and a beta of 0.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals during the 3rd quarter worth approximately $357,000. Geode Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter worth approximately $37,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter worth approximately $124,000. 4.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SHPH shares. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .